Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, Sergio Amadori

Blood (2008) 112 (4): 1147–1150.

https://doi.org/10.1182/blood-2007-12-129262

Published: 2008

Journal Articles

Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

Roberto Stasi, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Margherita M. Trawinska, Nichola Cooper, Sergio Amadori

Blood (2007) 110 (8): 2924–2930.

https://doi.org/10.1182/blood-2007-02-068999

Published: 2007

Journal Articles

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia

Roberto Stasi, Maurizio Brunetti, Elisa Stipa, Sergio Amadori

Blood (2004) 103 (12): 4424–4428.

https://doi.org/10.1182/blood-2003-11-4075

Published: 2004

Journal Articles

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

Roberto Stasi, Elisa Stipa, Vittorio Forte, Paola Meo, Sergio Amadori

Blood (2002) 99 (10): 3872–3873.

https://doi.org/10.1182/blood-2002-02-0392

Published: 2002

Journal Articles

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

Roberto Stasi, Adalberto Pagano, Elisa Stipa, Sergio Amadori

Blood (2001) 98 (4): 952–957.

https://doi.org/10.1182/blood.V98.4.952

Published: 2001

Journal Articles

Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia

Roberto Stasi, Giovanni Del Poeta, Adriano Venditti, Mario Masi, Elisa Stipa, Maria Christina Cox, Sergio Amadori

Blood (1998) 92 (2): 695–697.

https://doi.org/10.1182/blood.V92.2.695

Published: 1998

NARROW

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only